肺炎支原体(mycoplasma pneumoniae,MP)是目前儿童社区获得性肺炎中最常见的病原之一,发病率逐年升高,在非流行年间占小儿肺炎病原的10%~20%,流行年份则高达30%以上[1]。随着发病率的上升,难治性肺炎支原体肺炎的发生率也逐年升高。对这些患儿如果仅仅以全身抗生素治疗,往往疗程长且效果不佳,病情迁延反复,甚至发生肺不张、支气管扩张、闭塞性支气管炎、闭塞性细支气管炎、 Mycoplasma pneumoniae (MP) is one of the most common pathogen of community-acquired pneumonia in children at present, the incidence is increasing year by year, accounting for 10% -20% of children’s pneumonia pathogens in non-epidemic years, and up to 30% Above [1]. With the rising incidence, the incidence of refractory Mycoplasma pneumoniae pneumonia also increased year by year. If these children only treated with systemic antibiotics, often long course and the effect is not good, repeated delays in the disease, and even the occurrence of atelectasis, bronchiectasis, obliterative bronchiolitis, bronchiolitis obliterans,